A series of piperic acid derivatives were designed and synthesized from piperine/ piperlonguminine, and their antihyperlipidemic activities evaluated in dietinduced hyperlipidemic rats with respect to simvastatin. Two promising analogues 3 and 10 were discovered and their antihyperlipidemic activities were comparable to or better than those of simvastatin.
Hyperlipidemia (or dyslipidemia) is one of most common diseases in the U.S. affecting approximately one in every six adults. People with high cholesterol have approximately twice the risk for heart disease as people with lower levels [1a] . Therefore, treatment for hyperlipidemia is one of the most important public health challenges faced by the US health care system. Currently, statins remain the drug of choice for the treatment of hyperlipidemia [1b] . Unfortunately, their use has been associated with undesirable side effects, such as muscle pain [2a] and liver damage [2b]. These developments have spurred the search for new antihyperlipidemic compounds [3a] . Recently, our research group has identified three key antihyperlipidemic compounds, namely piperlonguminine, piperine and pipernonaline, from fruit of Piper longum L. used in traditional healing [3b,c] . Piperine and piperlonguminine are piperic acid amides with excellent in vivo lipid modulating activities on total cholesterol (TC), triglyceride (TG) and high density lipoprotein cholesterol (HDL-C) in diet-induced hyperlipidemic rats [3b]. To discover more interesting compounds, piperine and piperlonguminine were modified into piperic acid esters, which still retained highly antihyperlipidemic activity [4a] .
In this work, several piperic acid derivatives were designed, synthesized and their antihyperlipidemic activities tested with all the patented analogues [3c,4a] and simvastatin for comparison as summarized in Table 1 . Compared with the control group, simvastatin significantly decreased TC, TG and LDL-C, and slightly increased HDL-C. While piperine 1 had a significant effect on only two lipid parameters (TC and TG), piperlonguminine 2 showed significant activities on all four parameters (TC, TG and LDL-C and HDL-C). Overall, antihyperlipidemic activity of piperine 1 was lower than simvastatin, and piperlonguminine 2 had better lipid modulating activity than simvastatin, which are basically in agreement with published data [3b,4b] .
The 3,4-dihydroxy analogue 3 was prepared from piperine and significantly improved all lipid parameters (TC, TG, LDL-C and HDL-C) and was more effective than piperine 1 and simvastatin on HDL-C. However, ester analogue 4 was less active on both LDL-C and HDL-C, indicating that the hydroxyl groups may play an important role in modulating lipid activity. The amide moiety of piperine/piperlonguminine was modified in 5 -7 as shown in Table  1 . While n-butyl piperic acid amide 5 significantly decreased TC, TG and LDL-C, the n-hexyl analogue 6 only had significant impact on TG, hinting that the longer aliphatic chain of the amide moiety has a detrimental effect on antihyperlipidemic activity. Analogue 7 was made by replacement of the piperidine ring in piperine by pyrrolidine. Compared to the parent compound piperine 1, the antihyperlipidemic activity of 7 decreased, and its activities were similar to those of 6, suggesting a specific ring size in the amide moiety may be necessary for the antihyperlipidemic activity. Piperic acid 8, the base hydrolyzed product from piperine 1, has significantly decreased TC, TG and LDL-C levels, and had better activity on LDL-C than piperine 1 comparable to that of simvastatin. Piperic acid methyl ester 9 still showed significant antihyperlipidemic activity on TC, TG and LDL-C level, albeit the activity was decreased slightly compared to piperic acid 8.
Surprisingly, piperic acid ethyl ester 10 had significant activity on all four lipid parameters, and the activity on HDL-C was better than that of simvastatin. Piperic acid n-butyl ester 11 significantly modified TC, LDL-C and HDL-C, and slightly decreased TG. Piperic acid isobutyl ester 12 had significantly decreased LDL-C, and had almost no activity on the other three parameters (TC, TG and HDL-C). The n-octyl group renders analogue 13 ineffective, hinting that branched and longer side chain are unfavorable to the antihyperlipidemic activity of ester analogues. Although ester 12 is structurally similar to piperlonguminine 2, their lipid modulating activities were much different, suggesting that amide and ester functional groups may play a different role in their antihyperlipidemic activities. Analogue 14, lacking the 1,2methylenedioxybenzene group, showed a significant decrease in LDL-C level, and has minimal activity on TC, TG and HDL-C, emphasizing the importance of this group (see piperlonguminine 2 for comparison). Over the course of animal experiments, no significant body weight difference between control and drug treated groups was observed (data not shown), so these analogues may not have a high degree of acute toxicity in rats. a All analogues and simvastatin were orally administered (daily dose: 5.6 mg/kg body weight) for 15 days. b P < 0.05 significant (Students' t-test) and c P > 0.05 not significant from control animals.
In summary, twelve piperic acid analogues were synthesized from piperine/piperlonguminine, and in vivo antihyperlidemic assay showed that a longer side chain on an amide or ester moiety cannot be tolerated, and the 1,2-methylenedioxybenzene group is crucial. Two promising antihyperlidemic analogues 3 and 10 were discovered, and their activities on four lipid parameters were comparable to or better than simvastatin. Currently, more detailed studies on 3 and 10 toward drug development are underway.
Experimental
General: Piperine, (2E,4E)-2,4-hexadienoic acid, all the other reagents and solvents were purchased from Acros Organics or Sigma-Aldrich, China, and used without further purification. 1 H and 13 C NMR recorded at 500 and 125 MHz, respectively, using CDCl 3 (or DMSO-d 6 ) as a solvent.
Preparation of piperic acid 8: piperine (50.0 g, 175.0 mmol), LiOH (42.0 g, 1.75 mol), THF (80 mL) and H 2 O (80 mL) were carefully added into a 500 mL round bottom flask equipped with stir bar. The resulting mixture was refluxed at 80 o C overnight, and progress of the reaction was monitored by TLC. Once piperine was completely consumed, the reaction mixture was cooled to room temperature and acidified to pH=5 by aqueous HCl (1 M). The final mixture was extracted with ethyl acetate (200 mL) and H 2 O (30 mL x 3). The ethyl acetate layer was dried over Na 2 SO 4 , filtered and concentrated to give piperic acid (35.1 g, 92%) . amide analogue 2, 5, 6, 7 and 14: piperic acid (or (2E, 4E)-2,4-hexadienoic acid) (4.0 mmol), HATU (1.824 g, 4.8 mmol), DIEA (1390 uL, 8.0 mmol) and anhydrous DMF (15 mL) were mixed into a 50 mL round bottom flask equipped with stir bar, and the resulting solution stirred at room temperature for 15 min. The corresponding amine (8 mmol) was added, and stirring continued at room temperature overnight. The solution was extracted with ethyl acetate (40 mL) and H 2 O (10 mL x 3). The ethyl acetate layer was concentrated and purified by silica gel chromatography (25 % ethyl acetate in hexanes) to give the final analogues (yields: 65-90%).
Synthesis of

Synthesis of analogue 3:
At 0°C, a solution of boron tribromide (2.6 mL, 27.5 mmol) in dichloromethane (10 mL) was added dropwise to a solution of piperine (4.0 g, 14.0 mmol) in dichloromethane (50 mL). The mixture was stirred at room temperature for 2 h, and dried. The crude residue was purified by silica gel column chromatography (40 % ethyl acetate in hexanes) to give the title analogue (2.73 g, 71%).
Synthesis of analogue 4:
At 0 o C, acetyl chloride (1564 uL, 22.0 mmol) was added dropwise to a solution of 3 (1.0 g, 3.7 mmol) and Et 3 N (3088 uL, 22.2 mmol) in anhydrous dichloromethane (10 mL). The mixture was slowly warmed to room temperature and stirred for 2 h. The mixture was dried, extracted with ethyl acetate (40 mL) and H 2 O (10 mL x 3). The ethyl acetate layer was concentrated and purified by silica gel chromatography (25 % ethyl acetate in hexanes) to give analogue 4 (1.2 g, 91%). 9, 10, 11, 12 and 13: Piperic acid (872.0 mg, 4.0 mmol), the corresponding alcohol (10.0 mL) (for 13, toluene as solvent) and p-toluenesulfonic acid (69 mg, 0.4 mmol) were added carefully into a 50 mL round bottom flask equipped with stir bar. The resulting solution was refluxed until the esterification had finished. The solution was concentrated and purified by silica gel chromatography (25 % ethyl acetate in hexanes) to give the analogues (yields: 60-80 %).
Synthesis of analogues
Antihyperlipidemic activity test:
The antihyperlipidemic experimental design is similar to our previous report [3b,4c] .
